About Sequence Bio
Sequence Bio is a Healthcare company based in St. John's (Canada) founded in 2013. Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines. Sequence Bio has raised $5.47 million across 4 funding rounds from investors including Y Combinator, DCVC and Killick Capital. Its chief executive is Chris C Gardner. Sequence Bio offers products and services including Genetics Platform and Discovery Cohorts. Its focus areas include Life Sciences, Genomics, Genomics Services and Sequencing. Its legal entity is Sequence Bio, Inc. Its competitors include Omniome, Novogene Corporation, HitGen, Singular Genomics and Slingshot Bioscience and 5 more; 5 of its 10 listed competitors have raised funding.
Company details
Sequence Bio was established in 2013 in Newfoundland and Labrador, Canada, as a data-driven biotechnology company. A 100,000-person genome sequencing project is led by the firm to analyze genetic data for medical applications. Operations center on genomic research and data processing to support advancements in disease treatment and pharmaceutical development within the biotechnology sector. The company is headquartered in the region with Chris C. Gardner serving as CEO and President.
- Headquarters St. John's, Canada
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website sequencebio.com
- Social LinkedIn X Facebook
- Legal Name Sequence Bio, Inc.
- Total Equity Funding$5.47M (USD)
in 4 rounds
- Latest Funding Round$1.32M (USD), Seed
Jul 2019
- InvestorsY Combinator
& 4 more
Products & Services of Sequence Bio
Sequence Bio offers a comprehensive portfolio of products and services, including Genetics Platform and Discovery Cohorts.
Platform for systems biology to identify disease signals in genetics.
Service providing powered cohorts for disease research and drug development.
Funding Insights of Sequence Bio
Sequence Bio has successfully raised a total of $5.47M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $1.32 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.47M
- Total Rounds 4
- Last Round Seed — $1.32M
- First Round $1M
(Oct 2015)
- Investors Count 5
All 4 funding rounds of Sequence Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $1.32M | Seed | – | – | – |
| Jun 2019 | $150,000 | Seed | – | Y Combinator | – |
| Jun 2016 | $3M | Seed | – | DCVC | |
| Oct 2015 | $1M | Seed | – | Killick Capital |
5 investors in total: 5 institutional.
Investors in Sequence Bio
Sequence Bio has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Y Combinator, DCVC and Killick Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are accelerated via funding and educational programs. | – | ycombinator.com | Mountain View, United States | |
Venture capital firm focused on multiple sectors | – | dcvc.com | Palo Alto, United States | |
Killick Capital is engaged in private equity investments in Canada. | – | killickcapital.com | Canada | |
Family office backed private equity investment firm based out of Canada | – | klister.ca | Toronto, Canada | |
A venture capital fund focused on pre-seed investments in Newfoundland and Labrador. | 2015 | pelorusvc.com | Canada |
Investor details for Sequence Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sequence Bio
7 people are tracked at Sequence Bio (6 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Chris C Gardner | CEO & President | Leadership |
Bari Ballew | Senior Director of Data Science and Analytics | Leadership |
Sam Rasty | Chief Executive Officer and Board Director | Leadership |
David Phillips | Director of Finance & Administration | Leadership |
Chris McDonald | VP, Strategy and Market Development | Leadership |
Alain O'Dea | Senior Director, Technology & Security | Leadership |
Meg MacMillan | Computational Biologist | Team |
Complete people profiles for Sequence Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sequence Bio
3 dated milestones of Sequence Bio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Sequence Bio is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Seed, of $1.3M.
Competitors of Sequence Bio
Sequence Bio has 10 listed competitors in our database, 5 of them funded. They include Omniome, Novogene Corporation, HitGen, Singular Genomics and Slingshot Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| omniome.com | 2013 | San Diego, United States | $160.23M | 164 | Genome sequencing platform is provided for clinical diagnostics. | |
| novogene.com | 2011 | Beijing, China | $75M | 141 | Genomic services and solutions with NGS expertise are provided. | |
| hitgen.com | 2012 | Lanzhou, China | $39.11M | – | DNA-encoded libraries are developed for drug discovery applications. | |
| singulargenomics.com | 2016 | San Diego, United States | – | 169 | Next-generation gene sequencing and multi-omics technologies are provided. | |
| slingshotbio.com | 2012 | Berkeley, United States | $46.38M | 46 | Next-generation synthetic cells are developed for diagnostics and therapeutics. | |
| macrogen.com | 1997 | Seoul, South Korea | – | – | Next-generation sequencing and genomics services are provided globally. | |
| stemonix.com | 2014 | San Diego, United States | $33.7M | – | Developing a commercial scale printer for the high-volume growth and differentiation of stem cells and stem cell products. | |
| mgrc.com.my | 2004 | Kuala Lumpur, Malaysia | – | – | Genome sequencing, analysis, and genetic screening services are provided. | |
| genewiz.com | 1999 | South Plainfield, United States | – | 452 | Genomic services are provided for the life sciences industry. | |
| bgi.com | 1999 | Shenzhen, China | – | 25 | BGI is engaged in genomics and precision medicine solutions. |
Detailed competitors of Sequence Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sequence Bio
The website of Sequence Bio (sequencebio.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▼ 18.9% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Sequence Bio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sequence Bio
Complete news archive for Sequence Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sequence Bio
Sequence Bio was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Sequence Bio is headquartered in St. John's, Canada. It is registered at St. John's, Newfoundland And Labrador, Canada.
Chris C Gardner is the current CEO of Sequence Bio.
Sequence Bio is a funded company, having raised a total of $5.47M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Oct 2015.
Sequence Bio was established in 2013 in Newfoundland and Labrador, Canada, as a data-driven biotechnology company. A 100,000-person genome sequencing project is led by the firm to analyze genetic data for medical applications. Operations center on genomic research and data processing to support advancements in disease treatment and pharmaceutical development within the biotechnology sector. The company is headquartered in the region with Chris C. Gardner serving as CEO and President.
Sequence Bio's top competitors include Novogene Corporation, BGI and Singular Genomics.
Sequence Bio offers Genetics Platform and Discovery Cohorts.
Sequence Bio has 5 investors. Key investors include Y Combinator, DCVC, Killick Capital, Klister Credit, and Pelorus Venture Capital.
Sequence Bio operates through Sequence Bio, Inc..